Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD…

• NN
  National Natural Science Foundation of China

  Awards: 81822027, 81630090, 81822027, 2018ZX10301403, 81630090
• FU
  Fudan University
• CA
  Chinese Academy of Medical Sciences

  Award: 2019PT350002
• NK
  National Key Research and Development Program of China

  Awards: 2018ZX10301403, 2019YFA0904400
• SM
  Shanghai Medical College, Fudan University
• NM
  National Mega Project on Major Infectious Disease Prevention

  Award: 2018ZX10301403